RxDoctor Payments Data

Dewey Detar, DO

Family Medicine · Summerville, SCNPI 1750499604

Payments from drug & device makers

$316in general payments, 2019–2025

Across 10 payments — averaging $31.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$128
  • Amgen$55
  • Dexcom, Inc.$42
  • Boehringer Ingelheim$35
  • Abbott$27
  • Medtronic$14
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$316100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$316 in reported general payments places this provider in the 40th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$195,725
Medicare patients
418
Services billed
1,671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban585$217,624
JardianceEmpagliflozin132$46,918
XareltoRivaroxaban141$38,950
OzempicSemaglutide32$33,231
XifaxanRifaximin13$29,554
JanuviaSitagliptin Phosphate67$25,555
Risperdal ConstaRisperidone Microspheres13$25,095
NuedextaDextromethorphan Hbr/Quinidine21$20,216
TrulicityDulaglutide31$19,370
Xtampza ErOxycodone Myristate18$16,342
MyrbetriqMirabegron58$16,178
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$14,256
Memantine Hcl246$12,597
Atorvastatin Calcium631$11,809
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog66$8,095

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat$35$62,474161 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Summerville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →